Stratrix
On the Record · Davita

Davita acquisitions, on the record

The businesses Davita bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

BusinessDealWhenValue
Mozarc
Word for word“For example, in 2023 we closed a transaction with Medtronic, Inc. and one of its subsidiaries (collectively, Medtronic) to form a new, independent kidney care-focused medical device company (Mozarc).” 10-K for 2023
mergerin 2023—
international dialysis centers
Word for word“a net increase of 17 international dialysis centers from acquisitions and developments;” 10-K for 2023
acquisition——
U.S. dialysis centers sold and closed
Word for word“Sold and closed centers (2) (6) (22) (2) (9) Closed centers (3) (66) (112) (3) (2) Number of centers operated at end of year 2,675 2,724 367 350” 10-K for 2023
divestiture——
dialysis partnership (previously nonconsolidated, consolidated in Q1 2024)
Word for word“During the first quarter of 2024, we acquired a controlling interest in a previously nonconsolidated dialysis partnership for which we recognized a non-cash gain of $35.1 million on our prior investment upon consolidation.” 10-K for 2024
acquisitionfirst quarter of 2024—
APAC joint venture
Word for word“During the fourth quarter of 2024, we acquired a controlling interest in the previously nonconsolidated partnership known as the Company's APAC joint venture, for which we recognized a non-cash gain of $74.3 million on our prior investment upon consolidation.” 10-K for 2024
acquisitionfourth quarter of 2024—
physician services business
Word for word“Our IKC revenues were impacted by decreased revenues from our special needs plans and the divestiture of our physician services business, partially offset by a net increase in shared savings.” 10-K for 2024
divestiture——
previously nonconsolidated APAC joint venture partnership
Word for word“During 2024, we acquired a controlling interest in the previously nonconsolidated partnership known as the Company's APAC joint venture, for which we recognized a non-cash gain of $74.3 million on our prior investment upon consolidation.” 10-K for 2025
acquisitionDuring 2024$74.3 million
previously nonconsolidated dialysis partnership
Word for word“During 2024, we acquired a controlling interest in a previously nonconsolidated dialysis partnership for which we recognized a non-cash gain of $35.1 million on our prior investment upon consolidation.” 10-K for 2025
acquisitionDuring 2024$35.1 million
As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedCash paid for acquisitions (net of cash acquired)Goodwill from acquisitions
2016-12-31—$198.9 million
2017-12-31—$617 million
2018-12-31—$278.3 million
2019-12-31—$90.2 million
2020-12-31—$130.1 million
2021-12-31—$173.2 million
2022-12-31$57.3 million$49 million
2023-12-31$26.4 million$25.7 million
2024-12-31$246.1 million$349.1 million
2025-12-31$117.5 million$71.7 million

Deal filings since 2016

Read from Davita’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-11. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.